Eledon Pharmaceuticals(ELDN) - 2025 Q4 - Annual Results

Exhibit 99.1 Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft re ...